Biosimilars

What’s Next for the Biosimilars Market in the U.S.?

November 22, 2021

Momentum is building for biosimialrs but robust coverage for lower-cost agents, including biosimilars, is needed.

Priming the Pump for Interchangeable Biosimilars By Preferencing Semglee

November 04, 2021

By giving Semglee, the interchangeable biosimilar for Lantus, a preferred spot on its formulary, the Prime Therapeutics says it is setting the stage for other interchangeables coming down the pike, including the one for Humira.

Biosimilars Could Wind Up Saving $7.8 Billion in 2021, Says California Think Tank

November 04, 2021

Biosimilars can save states billions of dollars annually, according to a new report from a libertarian think tank in California.

Biosimilar Growth Impressive But New Policies Needed, AAM Exec Says

October 08, 2021

Three pieces of legislation that would provide incentives to prescribers and put generics and biosimilars in favorable formulary tiers would speed further prescribing and use of biosimilars, Christine Simmon told Managed Healthcare Executive.®

AAO Spokesperson: FDA Approval of Byooviz, First Biosimilar to Lucentis, Is “Significant"

October 07, 2021

Exactly how Byooviz will be priced is unclear, noted George W. Williams, M.D., a retina specialist and past president of the American Academy of Ophthalmology. The exact cost savings will help determine whether the biosimilar gains acceptance.

U.S. Saved $338 Billion via Biosimilars and Generics

September 21, 2021

The Association for Accessible Medicines said biosimilar drugs saved $7.9 billion in 2020, more than tripling the $2.5 billion saved in 2019.

FDA Clears First Biosimilar to Lucentis

September 20, 2021

The drug won't be available till next year but is expected to dent sales of Roche's blockbuster for age-related macular degeneration and other eye diseases.

Challenges in Biosimilar Acceptance, per Savitha Vivian of OptumRx

September 12, 2021

Senior Vice President of OptumRx, Savitha Vivian, shares with MHE when expected upcoming biosimilars are coming to market and the challenges she's seeing with biosimilar acceptance.

Optum Rx Executive: Biosimilars Have Momentum But It Will Take the Approval of Humira, Other Commonly Prescribed Biologics for Them to Really Take Off

September 11, 2021

In an interview with MHE, SVP Savitha Vivian said the biosimilars to Humira and Novolog that are expected to be on the market in the next few years could have the kind of impact that proponents of biosimilars have been hoping for.

Rituximab Biosimilars Produce Big Cost Savings, are Effective

September 07, 2021

A large Netherlands study demonstrated that rituximab biosimilars (R-biosimilars) produced a 43 percent reduction in annual costs. In addition, three-year overall survival did not differ between diffuse large B-cell lymphoma (DLBCL) and those receiving rituximab, according to the researchers.